Borimas Hanboonkunupakarn

Borimas' research focuses on improving the treatment of various tropical diseases with a special emphasis on malaria. She and the team at the Clinical Therapeutics Unit (CTU) have performed phase I/II clinical trials at the Bangkok Hospital for Tropical Diseases. The team demonstrated the safety, tolerability and pharmacokinetic interactions between the commonly used antimalarial combinations such as chloroquine plus primaquine and dihydroartemisinin-piperaquine plus primaquine, which supports the use of these combinations.

With the development and spread of artemisinin-resistant Plasmodium falciparum, Borimas’s specific research interests are about finding new tools to treat and control drug-resistant malaria. She and the team involved in a multi-country, open-label, randomised clinical trial (TRACII) to evaluate the efficacy, safety, and tolerability of triple artemisinin combination therapies (TACTs), which shows high treatment failure rate of dihydroartemisinin-piperaquine in Thailand, Cambodia and Vietnam. Her main current research topics are TACTs, controlled human malaria infection model, and ivermectin for malaria control.